In recent years, interest in the therapeutic potential of psychedelics — including psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) — has surged. Clinical trials have increasingly reported positive therapeutic and safety outcomes, fueling significant investment and the rapid emergence of a psychedelic industry. Hundreds of biotech and pharmaceutical companies have launched over the past decade, and psychedelics are now considered a multibillion-dollar sector with exceptional growth projections.
